Ultragenyx Pharma (RARE) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Ultragenyx Pharma (RARE) Has Multiple Catalysts in 2015 - Jefferies
March 26, 2015 8:36 AM EDTJefferies analyst Ryan Martins reiterated a Buy rating and $74 price target on Ultragenyx Pharma (NASDAQ: RARE) noting multiple catalysts in 2015.
Martins commented, "All of RARE's clinical programs are on track, with either phase 2 data or initiation of pivotal trials planned in 2015. Key updates included... More
Jefferies Weighs In on Ultragenyx Pharma (RARE) Related to SIMD Abstracts
March 25, 2015 7:34 AM EDTJefferies analyst Ryan Martins provided his take on SIMD abstracts relevant to Ultragenyx Pharma (NASDAQ: RARE). The firm reiterated a Buy rating and $74 price target.
Martins commented, "RARE will present 12 month data from the eIND patient on rhGUS, where we expect... More
